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In Transplantation Research we have recently published a
series of articles on the role of mammalian Target of Rapa-
mycin (mTOR) inhibitors [1–3]. This is a new departure
for the Journal, on which we hope to build in the future, of
publishing online conference supplements. The articles are
based on the most recent of a long-running annual confer-
ence, supported initially by Wyeth and subsequently by
Pfizer, following the introduction of sirolimus (Rapamune).
For me, this meeting gave delegates a unique experience,
and I doubt if any participant failed to learn something to
change their clinical practice. Using a combination of
didactic lectures, workshops and interactive sessions for
around 300 clinicians and 20–30 faculty members, the
design of the meeting promoted dialogue and exchange of
information. Perhaps the key aspect of the meeting was to
mix faculty, including some of the leading figures in trans-
plantation, with transplant clinicians from a range of back-
grounds in an informal atmosphere. Initially, the faculty
members were those involved in the development of siroli-
mus (SRL) and early clinical trials, but later involved those
with interests in infection, cardiovascular disease and can-
cer where there were specific issues or opportunities relat-
ing to the use of mTOR-inhibitors; and subsequently, to
the developing role of mTOR on cellular function and
cancer, intravascular stents, and other areas. The focus of
the meeting also evolved with time: initially devoted to
SRL, in later meetings this agent became the fulcrum for a
meeting that covered other emerging immunosuppres-
sants – including mTOR-inhibitors, such as everolimus,
novel agents such as belatacept, and much broader aspects
of transplant biology and management.
The long story of the discovery of SRL in the Easter
Islands (hence the name Rapamune) to its introduction
into clinical practice, is a fascinating tale [4, 5] – which
has been reported previously – and which owes its devel-
opment to Suren Sehgal, whose perseverance at Wyeth
kept the development going; to clinician-scientists like
Randy Morris who used it in an experimental setting, to
the clinicians who led the early human trials. Immediately
following its introduction, the aspiration was that SRL
would offer an alternative to calcineurin inhibition (CNI),
and avoid the adverse consequences of CNI on renal func-
tion. However, with time, it became apparent that – for the
majority of patients – SRL did not offer comparable im-
munosuppression to CNI and, that the side effect profile
was complex and sometimes difficult to manage. Around
this time the Symphony trial [6] established the efficacy of
a relatively simple regimen using tacrolimus (Tac), myco-
phenolate mofetil (MMF), and corticosteroids (CS), which
deterred clinicians – particularly those outwith academic
centres – from using novel agents. Subsequently, the place
of SRL has become more focussed: to use in patients where
CNI use has compromised graft function, in those with
malignancy or at high risk of malignancy, and in the man-
agement of patients with – or at high risk – of viral infec-
tions such as CMV or BK nephropathy. Currently, while
SRL is used in < 10 % of renal transplant recipients RTR),
for those who tolerate the agent well it offers advan-
tages with regard to long-term graft function, improved
blood pressure control with reduced antihypertensive
medication, and reduced risk of viral infections and
malignancy [1–3].
In this edition, Ed Giessler, a leading basic scientist in
experimental and human transplantation, reviews the
role of mTOR-inhibitors in cancer [1, 7]. Successful
transplantation is associated with an increase in the risk
of malignancy, most marked for skin tumours and par-
ticularly squamous cell carcinoma (SCC) and the aggres-
sive, cutaneous Merkel cell cancer – as a consequence ofCorrespondence: alan.jardine@glasgow.ac.uk
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immunosuppression. Registry data show that half of all
transplant recipients will develop some form of cancer
during their lifetime [1, 7]. It is difficult to have imag-
ined, even with hindsight, that mTORi would emerge as
effective treatments for cancer, given the negative impact
of previous agents on malignancy. However, various
mTORi – including derivatives of SRL, such as temsiroli-
mus – are now licenced for the treatment of a variety of
tumours including renal cancers and angiomyolipomas
(AML) associated with Tuberous Sclerosis Complex
(TSC). The first inkling of their efficacy came in the dem-
onstration that switching to SRL could regress Kaposi’s
sarcoma (1,7), later studies – highlighted in this article
have shown benefits of SRL in preventing the recurrence
of common skin cancers in RTR. In this, and other re-
views, the key role of mTOR in cell proliferation has been
explained in more detail [1, 7].
In the second article, Helio Tedesco-Silva and colleagues
review 15 years of experience of SRL in Sau Paulo, Brazil;
one of – if not the – largest kidney transplant centre in
the world. The size of their transplant population allowed
this centre, in collaboration with others, to lead a number
of early phase trials, and to study the possible benefits of
de novo low-dose CNI-SRL combinations and to use the
combination of SRL and Tac (when the latter agent
emerged as the CNI of choice, 6), and to study SRL in
combination with induction therapy using IL-2 receptor
blockade. The results, in studies involving many hundreds
of patients, show that it is possible to achieve similar acute
rejection rates, and comparable graft function with SRL-
CNI vs standard therapy but that even in the most experi-
enced centres, withdrawal due to adverse side effects is
higher with SRL, as is the incidence of clinically significant
proteinuria. However, in this centre –as observed else-
where – the incidence of CMV infection was halved in pa-
tients receiving SRL.
This centre was also involved in trials, following on
from the experience with de novo use above, to investigate
the use of a pre-determined switch from CNI to SRL.
Over the years, there have been a series of studies examin-
ing the potential benefits of switching at time points from
a few days to several months after transplantation [2, 3].
The findings of Tedesco-Silva et al., [2] mirror those of
other studies. Patients with minimal proteinuria and good
graft function, who tolerate SRL, did very well with better
graft function than those who continued on conventional
CNI based therapy. However, switching was associated
with a higher incidence of acute rejection (albeit with lim-
ited long term effects), proteinuria and withdrawal due to
intolerance.
These observations are consistent with more general
experience that SRL-based immunosuppression is asso-
ciated with very good graft function, but that its use is
difficult in clinical practice. “Therapeutic inertia” on the
part of both clinicians and patients has limited the use
of SRL for this reason, unless there is a driving clinical
indication – most commonly intolerance of CNI, or the
risk or presence of malignancy, or viral infections (CMV
and BK virus; 3).
In the third article, Fritz Diekmann and colleagues [3]
from Barcelona, present their extensive clinical experience
with SRL. Covering similar ground to the review above [2],
and providing an accessible table of the key studies, they
highlight the difficulties in switch protocols – from CNI
to mTOR-inhibitors – and the difficulties with “reactive”
switches in clinical practice, particularly when patients
have significant proteinuria. In spite of this, they see a
place for SRL based therapy in patients with CNI cosmetic
side effects and neurotoxicity, patients with or at risk of
BK and CMV infection and cancers, particularly those
with a viral aetiology. Perhaps the most important contri-
bution of this group has been to inform and help patients,
and clinicians, to manage side effects including mouth ul-
cers and skin rashes, to allow patients to continue with
SRL in the longer term and the importance of targeting
lower trough levels.
There are few new agents for transplant immunosup-
pression, either in development or that have come into
clinical practice since the introduction of SRL. The diffi-
culty in developing new agents for a relatively small thera-
peutic indication and market, and the limitations of the
conventional composite trial endpoint – acute rejection,
graft loss, death and loss to follow-up – have deterred
pharmaceutical companies from investment in this area.
The recent history of clinical trials has been early discon-
tinuation of clinical development programmes (e.g. FTY-
720 and AEB-071), and only belatacept has been licenced
for clinical use, with limited impact. Although transplant
outcomes have improved dramatically in the last 40 years,
the agents we use have toxicity that would be unaccept-
able in other clinical areas, and most agents require close
monitoring of drug levels. The SRL “story” outlined in the
articles in this supplement illustrates how the indications
for SRL use have evolved with time as we have understood
the mechanisms of action, and moved to lower dose and
target levels – a “story” that is not dissimilar to the other
agents in clinical use. For SRL, it now appears that de novo
use is impractical in most centres, and that its place is to
minimise or replace CNI in patients with CNI related tox-
icity; and those with or at risk of viral infections or malig-
nancy. These indications limit use to 5–10 % of the total
transplant population; a subgroup for whom it is the best
agent, with a key role. However, there are large regional
variations. SRL may be favoured in regions where CMV
seropositivity is high and the cost of universal prophylaxis
prohibitive; and in regions where the rate of cancer is
high, such as the countries in South East Asia with high
levels of genitourinary malignancy. The development of
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SRL has taught us many things, not least the unexpected
role of mTOR in cancer, and with the “retrospectroscope”
one wonders if SRL had been developed first would we be
asking ourselves whether to use CNI that are, perhaps,
easier to use but are associated with an unacceptable risk
of post-transplant malignancy?
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